CEO Michael Cannon-Brookes reported Atlassian closed FY '25 with "stellar execution from our enterprise sales teams and partner teams," generating over $5.2 billion in revenue and over $1.4 billion in ...

The CEO, Kristian Johansen, highlighted total revenues of $492 million for Q4 2024, reflecting a 19% increase from the same period in 2023. EBIT nearly doubled to $92 million, with a margin of 19%.

Prothena plans to announce results from the Phase 3 AFFIRM-AL trial for birtamimab in Q2 2025, targeting a U.S. launch by the second half of 2026, pending regulatory approval. Initial data from the ...